OpGen, Inc. (NASDAQ:OPGN) Short Interest Update

OpGen, Inc. (NASDAQ:OPGN) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 20,800 shares, a decrease of 47.3% from the February 29th total of 39,500 shares. Based on an average daily trading volume, of 1,470,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.2% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on OpGen in a report on Thursday, March 21st. They issued a “sell” rating for the company.

OpGen Stock Performance

OPGN traded down $0.02 on Thursday, reaching $0.70. The company’s stock had a trading volume of 1,581,480 shares, compared to its average volume of 1,638,011. The stock has a 50 day moving average of $0.44 and a two-hundred day moving average of $0.46. OpGen has a fifty-two week low of $0.17 and a fifty-two week high of $3.84.

Institutional Investors Weigh In On OpGen

Several large investors have recently modified their holdings of OPGN. HRT Financial LP acquired a new stake in shares of OpGen in the fourth quarter valued at approximately $26,000. Citadel Advisors LLC raised its stake in shares of OpGen by 571.0% during the third quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock worth $29,000 after purchasing an additional 85,754 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of OpGen during the first quarter worth approximately $49,000. Finally, Vanguard Group Inc. raised its stake in shares of OpGen by 39.8% during the third quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock worth $537,000 after purchasing an additional 534,960 shares during the last quarter. 2.68% of the stock is owned by institutional investors and hedge funds.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.